Status:
COMPLETED
A Study of Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer
Lead Sponsor:
BeiGene
Conditions:
Non-Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The main objective of this study was to evaluate the anti-tumor activity of gimistotug (BGB-A445) plus investigational agents in participants with non-small cell lung cancer (NSCLC).
Detailed Description
This study tested whether gimistotug in combination with other agents could help treat participants with non-small cell lung cancer (NSCLC) who were already treated with other anticancer agents, inclu...
Eligibility Criteria
Inclusion
- Advanced or metastatic NSCLC (nonsquamous or squamous) that is histologically or cytologically confirmed
- Participants who have received no more than 2 lines of prior systemic therapies which must include anti-programmed cell death protein ligand-1 (anti-PD-(L)1) treatment and a platinum-based chemotherapy administered in combination with, or sequentially before or after the anti-PD-(L)1 treatment
- At least 1 measurable lesion as defined per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- Adequate organ function as indicated by laboratory values during screening
Exclusion
- With mixed small cell lung cancer
- Has received prior therapy targeting OX40 or any other T-cell agonists
- Has received prior therapy containing docetaxel and/or ramucirumab for advanced or metastatic NSCLC
- Has received any Chinese herbal medicine or Chinese patent medicines used to control cancer ≤ 14 days before the first dose of study drug(s)
- Active leptomeningeal disease or uncontrolled and untreated brain metastasis
- NOTE: Other criteria may apply
Key Trial Info
Start Date :
October 23 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2024
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT06029127
Start Date
October 23 2023
End Date
December 31 2024
Last Update
January 5 2026
Active Locations (18)
Enter a location and click search to find clinical trials sorted by distance.
1
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China, 100021
2
Daping Hospital, Third Military Medical University
Chongqing, Chongqing Municipality, China, 400042
3
Gansu Provincial Hospital
Lanzhou, Gansu, China, 730000
4
The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine
Guangzhou, Guangdong, China, 510405